June 2016June 2016
New Product - Uptravi
Uptravi (selexipag) is an oral, selective, IP prostacyclin receptor agonist, and is structurally and pharmacologically distinct from prostacyclin and its analogues. Stimulation of the IP receptor by selexipag and the active metabolite leads to vasodilatory as well as anti-proliferative and anti‑fibrotic effects. Uptravi is indicated for the treatment of idiopathic pulmonary arterial hypertension, heritable pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue disease, pulmonary arterial hypertension associated with congenital heart disease with repaired shunts, pulmonary arterial hypertension associated with drugs and toxins in patients with WHO functional class II, III or IV symptoms. Uptravi is contraindicated in patients with severe hepatic impairment (Child‑Pugh class C); severe coronary heart disease or unstable angina; myocardial infarction within the last 6 months; decompensated cardiac failure if not under close medical supervision; severe arrhythmias; cerebrovascular events (e.g., transient ischaemic attack, stroke) within the last 3 months and congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension. Uptravi is available as 200 mcg tablets in packs of 60’s and 140’s; 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg and 1600 mcg tablets in packs of 60’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au